You are here
Management of Targeted Therapies: skin toxicities of innovative treatments
By Vincent Sibaud, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
Vincent Sibaud stresses the importance of supportive onco-dermatology and regular dermatological monitoring of patients receiving targeted therapies. Most of the receptors that are inhibited in targeted therapy (e.g. EGFR) are physiologically expressed in the skin; therefore, stopping tumour growth frequently leads to a dysregulation of skin homeostasis. Dermatologic toxicities include, for example, hyperkeratotic lesions, fissures and xerosis, vitiligoid and aphtous lesions as well as toxic erythema.
Vincent Sibaud, Institut Claudius Regaud, Toulouse, France